IPH4502 is a novel and differentiated exatecan ADC targeting Nectin-4, currently investigated in a Phase 1 clinical trial in advanced solid tumors.
IPH4502 demonstrated preclinical anti-tumor efficacy in models of primary and acquired resistance to enfortumab vedotin and in tumors with low to moderate levels of Nectin-4 expression, extending its potential beyond urothelial carcinoma.
Jonathan Dickinson, CEO of Innate, to present in a Showcase Session at the AACR Oncology Industry Partnering Event.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding IPH4502, its novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4, has been selected for the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30 in Chicago, Illinois.
In addition, Jonathan Dickinson, CEO of Innate Parma, will present in a showcase session at the AACR Oncology Industry Partnering Event, to give an update on Innate’s pipeline and strategy.
Presentation details
AACR 2025 ANNUAL MEETING
- IPH4502, a differentiated Nectin-4 exatecan antibody-drug conjugate
Abstract Number: 5443
Session Type: Poster session
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibody-Based Cancer Therapeutics 3
Session Date/Time: Tuesday Apr 29, 2025 2:00 PM – 5:00 PM
More information can be found on the AACR website.
AACR ONCOLOGY INDUSTRY PARTNERING EVENT
- Showcase Session 2 | W192
Presenter: Jonathan Dickinson, Chief Executive Officer
Date and Time: Thursday Apr 24, 2025 4:50 PM
Location: McCormick Place Convention Center West Building, Chicago, Illinois
More information can be found on the AACR Oncology Industry Partnering Event website.
About IPH4502
IPH4502 is a novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) conjugated to exatecan targeting Nectin-4, a cell adhesion molecule that is overexpressed in several types of solid tumors, such as urothelial carcinoma, breast cancer, non-small cell lung cancer or gastro-intestinal tract cancer.
IPH4502 is currently investigated in a Phase 1 trial in advanced solid tumors. The Phase 1 trial includes a dose escalation part 1 and a dose optimization part 2 and will assess the safety, tolerability, and preliminary efficacy of IPH4502 in different solid tumors known to express Nectin-4, including but not limited to urothelial carcinoma, non-small cell lung, breast, ovarian, gastric, esophageal, and colorectal cancers. The study plans to enroll approximately 105 patients.
In preclinical models, IPH4502 demonstrates strong bystander killing effect, and efficient internalization, enabling a potent anti-tumor activity in models with various Nectin-4 expression levels. Additionally, IPH4502 shows efficacy in models resistant to MMAE-ADC. These results support its potential for development beyond UC and in cancer patients treated with MMAE-based ADCs.
| Press Release in English | 207.09 KB |
| Communiqué de presse en français | 147.31 KB |